The Foundation for Angelman Syndrome Therapeutics Australia (or FAST) is an organisation of families and professionals dedicated to finding a cure for Angelman Syndrome and related disorders through funding research, education and advocacy. The Foundation is committed to assisting individuals living with Angelman Syndrome to realise their full potential and quality of life.
Angelman Syndrome (or AS) is a neurodevelopmental disorder affecting approximately 1 in 15,000 live births. Although the cause of AS is known, there are currently no treatments available for this disorder. FAST is committed to funding the research that will lead to treatments and eventually a cure. Learn about Angelman Syndrome and why we believe a cure is within reach....
|
New look website
Welcome to our new look website! This site is aimed at empowering families, professionals and researchers to provide the best possible solutions to support those affected by Angelman Syndrome. Our new site will give you access to Australian and international information. Join here to keep up to date with news, announcements and tailored content ....
|
|
Human clinical trials
FAST United States (FAST US) are preparing to launch Human Clinical Trials shortly using an FDA approved drug to treat Angelman Syndrome (for more details read our latest US Newsletter); FAST Australia is working closely with Dr. Weeber and FAST-US to ensure that any trials have the ability to be replicated in Australia if required. Watch this space!
|
|
Australian research announcement
FAST Australia together with the Mater Hospital & Mater Medical Research Institute are undertaking our first research project; the Angelman Syndrome Register. The register will be a “first of its kind” collection of AS patients, related medical professionals and researchers who can be contacted in the event of the development of a relevant research study, participation in a trial, a therapeutic or a cure. Read more or join here....
|
|
Introducing Australian Scientific Advisory Board
Some of Australia's brightest minds have come together to work collaboratively with our United States SAB towards our common goal for a therapeutic to treat Angelman Syndrome. Read more here....
|
